Overview

Study Evaluating Bifeprunox in Bipolar Depression

Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of the study is to investigate whether eight weeks of treatment with flexible doses of Bifeprunox is superior to treatment with placebo in depressed patients with bipolar disorder.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Collaborator:
Solvay Pharmaceuticals
Criteria
Inclusion Criteria:

- Men and women 18 to 65 years of age, inclusive.

- Diagnosis of Bipolar Disorder and must be experiencing a depressive episode.

Exclusion Criteria:

- This is a follow on study to protocol 3168A2-304. Only subjects who have participated
in the previous study are eligible.